CAUTION: In the U.S. TheraSphere™ GBM is under an investigational device exemption for treatment of patients with recurrent glioblastoma and limited by Federal (or US) law to investigational use. The safety and effectiveness for this treatment has not been established.
FRONTIER study overview
The FRONTIER study is a first-in-human feasibility study assessing the use of TheraSphere™ GBM Y-90 Glass Microspheres in patients with recurrent glioblastoma (GBM). The purpose of the study is to evaluate the safety and feasibility of using this therapy in the brain to treat recurrent GBM.